Capecitabine

Usual Dosing (Adults)

Colorectal / Breast cancer: Recommended dose: 1250 mg/m2 po bid (morning and evening; equivalent to 2500 mg/m 2 total daily dose) x 2 weeks followed by a 1-week rest period given as 3-week cycles. Tablets should be swallowed with water within 30 minutes after a meal. In combination with docetaxel, the recommended dose of XELODA is 1250 mg/m2 bid x 2 weeks followed by a 1-week rest period, combined with docetaxel at 75 mg/m2 as a 1-hour intravenous infusion every 3 weeks.

Maintenance dose: Subsequent dose adjustment is recommended as outlined in the package insert if a patient develops a grade 2 to 4 adverse event. SEE PACKAGE INSERT FOR DOSAGE MODIFICATIONS BASED ON TOXICITY LEVELS.

Renal Dosing

[CRCL >51-80 ml/min]:
No changes to the starting dose.

[30-50]:
A dose reduction to 75% of the XELODA starting dose when used as monotherapy or in combination with docetaxel (from 1250 mg/m2 to 950 mg/m2 twice daily) is recommended.

Subsequent dose adjustment is recommended as outlined in the package insert if a patient develops a grade 2 to 4 adverse event. SEE PACKAGE INSERT FOR DOSAGE MODIFICATIONS BASED ON TOXICITY LEVELS.

Hemodialysis

Specific guidelines not available.

Reference(s)

National Institutes of Health, U.S. National Library of Medicine, DailyMed Database.
Provides access to the latest drug monographs submitted to the Food and Drug Administration (FDA). Please review the latest applicable package insert for additional information and possible updates. A local search option of this data can be found here.